Master Alliance Provisions Guide (MAPGuide)

All Agreements

(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Agreement
Advance Purchase Agreement for the Development, Production, Advance Purchase and Supply of a COVID-19 Vaccine for EU Member States with CureVac
2020
Government
Pharmaceutical manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Donation
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [access-to-medicines.pandemic-products.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 266
            [slug] => pandemic-products
            [title] => Pandemic Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Pandemic Products
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [access-to-medicines.pandemic-products.curevac-ec-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 266
            [slug] => pandemic-products
            [title] => Pandemic Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Pandemic Products
            [provision_id] => 2470
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-14/
            [children] => 
        )

    [access-to-medicines.supply-purchase-of-products.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [business-model.royalties-and-payments.curevac-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2475
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [consortium-structure. .curevac-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 2483
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [information-sharing.confidentiality.curevac-ec-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2481
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-4/
            [children] => 
        )

    [information-sharing.data-management.curevac-ec-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 2478
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.curevac-ec-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2478
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [ip-ownership.exploitation-results.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 2476
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [ip-ownership.ownership-results.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2476
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [liability.indemnity.curevac-ec-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 2479
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-6/
            [children] => 
        )

    [liability.insurance.curevac-ec-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 2480
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [liability.limitation-of-liability.curevac-ec-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2480
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [liability.warranties.curevac-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2474
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [other.conflict-of-interest.curevac-ec-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 59
            [slug] => conflict-of-interest
            [title] => Conflict of Interest
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Conflict of Interest
            [provision_id] => 2472
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-13/
            [children] => 
        )

    [other.dispute-resolution.curevac-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 267
            [slug] => dispute-resolution
            [title] => Dispute resolution
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Dispute resolution
            [provision_id] => 2477
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [other.regulatory-strategy.curevac-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2473
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [term-and-termination.effect-of-termination.curevac-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 2482
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.curevac-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2482
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

)
Advance Purchase Agreement for the Production, Purchase and Supply of a COVID-19 Vaccine in the European Union with AstraZeneca
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Donation
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [access-to-medicines.equitable-access.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [access-to-medicines.pandemic-products.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 266
            [slug] => pandemic-products
            [title] => Pandemic Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Pandemic Products
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [business-model.royalties-and-payments.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2543
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [consortium-structure. .astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 2554
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2549
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

    [information-sharing.data-management.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 2546
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6/
            [children] => 
        )

    [ip-ownership.exploitation-results.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [ip-ownership.ownership-results.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [liability.indemnity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 2547
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [liability.limitation-of-liability.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2548
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4/
            [children] => 
        )

    [liability.warranties.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2542
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [other.dispute-resolution.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 267
            [slug] => dispute-resolution
            [title] => Dispute resolution
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Dispute resolution
            [provision_id] => 2545
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [other.regulatory-strategy.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2541
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

)
Aridis-PATH Vaccine Formulation Agreement
2007
Biotechnology company
Product development partnership
Vaccine
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [access-to-medicines.pricing.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable or reasonable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Affordable or reasonable pricing
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [information-sharing.confidentiality.aridis-path-vaccine-formulation-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1240
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.protection-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.sublicensee.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 108
            [slug] => sublicensee
            [title] => Sublicenses
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Sublicenses
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [liability.limitation-of-liability.aridis-path-vaccine-formulation-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1275
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-5/
            [children] => 
        )

    [term-and-termination.effect-of-termination.aridis-path-vaccine-formulation-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 1284
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

)
AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
2020
Government
Multinational pharmaceutical company
Vaccine
Commercialization
Array
(
    [access-to-medicines.donation.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Donation
            [provision_id] => 2964
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7/
            [children] => 
        )

    [access-to-medicines.supply-purchase-of-products.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2949
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5/
            [children] => 
        )

    [business-model.royalties-and-payments.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2947
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9/
            [children] => 
        )

    [information-sharing.confidentiality.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2956
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 2945
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222/
            [children] => 
        )

    [ip-ownership.ownership-results.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2945
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222/
            [children] => 
        )

    [liability.limitation-of-liability.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2957
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4/
            [children] => 
        )

    [liability.warranties.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2958
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6/
            [children] => 
        )

    [other.regulatory-strategy.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2965
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 2962
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3/
            [children] => 
        )

    [term-and-termination.term-of-agreement.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2960
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2961
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11/
            [children] => 
        )

)
AUTM Model Inter-Institutional Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.benefit-revenue-sharing.autm-model-iia-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit/revenue sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit/revenue sharing
            [provision_id] => 1182
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
            [children] => 
        )

    [consortium-structure. .autm] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1291
            [provision_permalink] => https://ghiaa.org/provision_document/autm/
            [children] => 
        )

    [information-sharing.confidentiality.autm-model-iia-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1243
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-5/
            [children] => 
        )

    [ip-ownership.exceptions-ip-ownership.autm-model-iia-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 93
            [slug] => exceptions-ip-ownership
            [title] => Exceptions or limitations to the IP ownership rules
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exceptions or limitations to the IP ownership rules
            [provision_id] => 1186
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.autm-model-iia-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1182
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
            [children] => 
        )

    [ip-ownership.protection-results.autm-model-iia] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1164
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia/
            [children] => 
        )

    [liability.limitation-of-liability.autm-model-iia-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1273
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-6/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1259
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-9/
            [children] => 
        )

    [term-and-termination.term-of-agreement.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

)
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
  • No Issues
Award Contract No. W911QY20C0100, by and between ModernaTX, Inc. and the Department of Defense
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.pandemic-products.moderna-dod-supply-agreement-for-mrna-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 266
            [slug] => pandemic-products
            [title] => Pandemic Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Pandemic Products
            [provision_id] => 2452
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-4/
            [children] => 
        )

    [access-to-medicines.supply-purchase-of-products.moderna-dod-supply-agreement-for-mrna-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2452
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-4/
            [children] => 
        )

    [information-sharing.confidentiality.moderna-dod-supply-agreement-for-mrna-vaccine] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2448
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine/
            [children] => 
        )

    [information-sharing.data-management.moderna-dod-supply-agreement-for-mrna-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 2454
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-5/
            [children] => 
        )

    [liability.limitation-of-liability.moderna-dod-supply-agreement-for-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2450
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-3/
            [children] => 
        )

    [other.regulatory-strategy.moderna-dod-supply-agreement-for-mrna-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2449
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-2/
            [children] => 
        )

)
Boston University Startup Exclusive License
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.use-background-ip.bu-startup-exclusive-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1127
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license/
            [children] => 
        )

    [liability.limitation-of-liability.bu-startup-exclusive-license-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1272
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license-2/
            [children] => 
        )

)
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
General Industry
Device
Diagnostic
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.carb-x-research-subaward-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1187
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-2/
            [children] => 
        )

    [ip-ownership.access-results.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1173
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
            [children] => 
        )

    [ip-ownership.exploitation-results.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1173
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
            [children] => 
        )

    [open-science.open-sciences.carb-x-research-subaward-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1218
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-3/
            [children] => 
        )

)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
General Industry
Government
Other nonprofit
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.cavd-data-materials-sharing-agreement-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1250
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2-2/
            [children] => 
        )

    [information-sharing.confidentiality.cavd-data-materials-sharing-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1251
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1254
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
            [children] => 
        )

    [information-sharing.data-management.cavd-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1231
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-4/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.cavd-data-materials-sharing-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1251
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-3/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1254
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cavd-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 1231
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-4/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.cavd-data-materials-sharing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1109
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1134
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
            [children] => 
        )

)
CEPI CfP3i Template Funding Agreement
2018
Funder
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1203
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1202
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-cfp3i-template-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Outbreak preparedness
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Outbreak preparedness
            [provision_id] => 1204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.public-health-licenses.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 107
            [slug] => public-health-licenses
            [title] => Public health licenses
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Public health licenses
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit/revenue sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit/revenue sharing
            [provision_id] => 1203
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-results.cepi-cfp3i-template-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1159
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-cfp3i-template-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 996
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-8/
            [children] => 
        )

    [open-science.open-data.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1221
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
            [children] => 
        )

    [open-science.open-data.cepi-cfpi3-template-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1222
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement-2/
            [children] => 
        )

    [open-science.open-sciences.cepi-cfpi3-template-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1222
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement-2/
            [children] => 
        )

    [open-science.publication.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1221
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
            [children] => 
        )

)
Collaboration and License Agreement between Sanofi and Translate Bio, as Amended
2020
Biotechnology company
Multinational pharmaceutical company
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.donation.sanofi-translate-bio-collaboration-and-license-agreement-as-amended] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Donation
            [provision_id] => 2422
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended/
            [children] => 
        )

    [access-to-medicines.pandemic-products.sanofi-translate-bio-collaboration-and-license-agreement-as-amended] => GHIAA2019\IssueItem Object
        (
            [ID] => 266
            [slug] => pandemic-products
            [title] => Pandemic Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Pandemic Products
            [provision_id] => 2422
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended/
            [children] => 
        )

    [business-model.royalties-and-payments.sanofi-translate-bio-collaboration-and-license-agreement-as-amended] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2422
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended/
            [children] => 
        )

    [information-sharing.technology-transfer.sanofi-translate-bio-collaboration-and-license-agreement-as-amended] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 2422
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended/
            [children] => 
        )

    [information-sharing.technology-transfer.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 2426
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3/
            [children] => 
        )

    [ip-ownership.ownership-results.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2424
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2/
            [children] => 
        )

    [open-science.publication.sanofi-translate-bio-collaboration-and-license-agreement-as-amended] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 2422
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended/
            [children] => 
        )

    [other.dispute-resolution.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 267
            [slug] => dispute-resolution
            [title] => Dispute resolution
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Dispute resolution
            [provision_id] => 2425
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.sanofi-translate-bio-collaboration-and-license-agreement-as-amended] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2422
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended/
            [children] => 
        )

)
Ebola WHO-Manufacturer LOA (Annex)
2015
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [information-sharing. .ebola-who-manufacturer-loa-annex] => GHIAA2019\IssueItem Object
        (
            [ID] => 49
            [slug] => information-sharing
            [title] => Information sharing & data safety
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Information sharing & data safety
            [provision_id] => 1227
            [provision_permalink] => https://ghiaa.org/provision_document/ebola-who-manufacturer-loa-annex/
            [children] => 
        )

    [information-sharing.confidentiality.ebola-who-manufacturer-loa-annex] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1227
            [provision_permalink] => https://ghiaa.org/provision_document/ebola-who-manufacturer-loa-annex/
            [children] => 
        )

)
EDCTP2 Policy on Clinical Trials
2018
Funder
Device
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [open-science.open-data.edctp2-policy-on-clinical-trials-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1215
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-2/
            [children] => 
        )

    [open-science.open-data.edctp2-policy-on-clinical-trials-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1217
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-3/
            [children] => 
        )

    [open-science.open-sciences.edctp2-policy-on-clinical-trials] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1216
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials/
            [children] => 
        )

    [open-science.open-sciences.edctp2-policy-on-clinical-trials-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1215
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-2/
            [children] => 
        )

    [open-science.publication.edctp2-policy-on-clinical-trials] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1216
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials/
            [children] => 
        )

)
Funder Development Partnering Agreement
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.equitable-access.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1200
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
            [children] => 
        )

    [access-to-medicines.funder-step-in.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 103
            [slug] => funder-step-in
            [title] => Funder step-in rights
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Funder step-in rights
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.funder-development-partnering-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Outbreak preparedness
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Outbreak preparedness
            [provision_id] => 1198
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-6/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit/revenue sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit/revenue sharing
            [provision_id] => 1200
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
            [children] => 
        )

    [ip-ownership.access-results.funder-development-partnering-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1175
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.funder-development-partnering-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1184
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.funder-development-partnering-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1158
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.funder-development-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1170
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.funder-development-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1139
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement/
            [children] => 
        )

    [liability.limitation-of-liability.funder-development-partnering-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1274
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-10/
            [children] => 
        )

)
Gates Foundation Open Access Policy
2015
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [open-science.open-data.1393] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1393
            [provision_permalink] => https://ghiaa.org/provision_document/1393/
            [children] => 
        )

    [open-science.open-sciences.1393] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1393
            [provision_permalink] => https://ghiaa.org/provision_document/1393/
            [children] => 
        )

    [open-science.publication.1393] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1393
            [provision_permalink] => https://ghiaa.org/provision_document/1393/
            [children] => 
        )

)
Gates Foundation Sample Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1395
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2/
            [children] => 
        )

    [open-science.publication.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1394
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement/
            [children] => 
        )

)
Gilead-Indian Manufacturers HCV License Agreement
2014
Multinational pharmaceutical company
Pharmaceutical manufacturer
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.access-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.ownership-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.gilead-hcv-license-agreement-with-indian-generic-manufacturers] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1137
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers/
            [children] => 
        )

    [liability.insurance.gilead-hcv-license-agreement-with-indian-generic-manufacturers-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 1264
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-3/
            [children] => 
        )

)
Global Access Commitment & Humanitarian License
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

    [access-to-medicines.public-health-licenses.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 107
            [slug] => public-health-licenses
            [title] => Public health licenses
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Public health licenses
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

)
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.access-results.imi-1-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1171
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-1-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1111
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-1-model-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1147
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-2/
            [children] => 
        )

)
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .imi-2-joint-undertaking-model-consortium-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1307
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.imi-2-joint-undertaking-model-consortium-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1245
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-5/
            [children] => 
        )

    [information-sharing.data-management.imi-2-joint-undertaking-model-consortium-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1257
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-6/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.imi-2-joint-undertaking-model-consortium-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1306
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-10/
            [children] => 
        )

    [information-sharing.material-transfer.imi-2-joint-undertaking-model-consortium-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1237
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-4/
            [children] => 
        )

    [ip-ownership.access-results.imi-2-joint-undertaking-model-consortium-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 3211
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.1305] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1305
            [provision_permalink] => https://ghiaa.org/provision_document/1305/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1309
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-2-joint-undertaking-model-consortium-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1304
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-9/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-joint-undertaking-model-consortium-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1166
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1132
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [liability.indemnity.imi-2-joint-undertaking-model-consortium-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1266
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-8/
            [children] => 
        )

    [liability.limitation-of-liability.imi-2-joint-undertaking-model-consortium-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1261
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-7/
            [children] => 
        )

    [liability.warranties.imi-2-joint-undertaking-model-consortium-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1261
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-7/
            [children] => 
        )

)
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .imi-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1288
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2/
            [children] => 
        )

    [information-sharing.confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1253
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1253
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
            [children] => 
        )

    [ip-ownership.access-results.imi-2-model-grant-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1172
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.imi-2-model-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1178
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-2-model-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1308
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-12/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-2-model-grant-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1303
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-10/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1165
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1128
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement/
            [children] => 
        )

    [liability.limitation-of-liability.imi-2-model-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1268
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-9/
            [children] => 
        )

    [open-science.open-data.imi-2-model-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1211
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-6/
            [children] => 
        )

)
Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
2021
Biotechnology company
Government
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [consortium-structure. .2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [consortium-structure. .israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 2865
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2869
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.data-management.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 2868
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2868
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 2872
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2872
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5/
            [children] => 
        )

    [liability.warranties.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2870
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4/
            [children] => 
        )

    [open-science.publication.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 2873
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6/
            [children] => 
        )

)
Lambert Agreement D
2019
Academic institution
General Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .lambert-agreement-d-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1293
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-13/
            [children] => 
        )

    [information-sharing.confidentiality.lambert-agreement-d-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1239
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-5/
            [children] => 
        )

    [information-sharing.confidentiality.lambert-agreement-d-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1252
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-6/
            [children] => 
        )

    [information-sharing.data-management.lambert-agreement-d-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1255
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-7/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.lambert-agreement-d-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1252
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-6/
            [children] => 
        )

    [ip-ownership.exceptions-ip-ownership.lambert-agreement-d-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 93
            [slug] => exceptions-ip-ownership
            [title] => Exceptions or limitations to the IP ownership rules
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exceptions or limitations to the IP ownership rules
            [provision_id] => 1185
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.lambert-agreement-d-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1177
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.lambert-agreement-d] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1107
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d/
            [children] => 
        )

    [ip-ownership.ownership-results.lambert-agreement-d-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1141
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.lambert-agreement-d-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1113
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-15/
            [children] => 
        )

    [liability.indemnity.lambert-agreement-d-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1262
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-10/
            [children] => 
        )

    [liability.limitation-of-liability.lambert-agreement-d-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1269
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-11/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1258
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-8/
            [children] => 
        )

    [open-science.open-sciences.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1214
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
            [children] => 
        )

    [open-science.publication.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1214
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.lambert-agreement-d-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1281
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-12/
            [children] => 
        )

)
Merck-BSC License Collaboration Agreement
2014
Biotechnology company
Multinational pharmaceutical company
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [information-sharing.confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1242
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1242
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
            [children] => 
        )

    [information-sharing.technology-transfer.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1235
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1112
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation/
            [children] => 
        )

    [ip-ownership.ownership-results.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1162
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3/
            [children] => 
        )

    [ip-ownership.protection-results.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1162
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1140
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2/
            [children] => 
        )

    [liability.indemnity.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1267
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7/
            [children] => 
        )

    [liability.limitation-of-liability.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1276
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 1287
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

)
Moderna – BARDA Agreement (Contract No.75A50122C00034 for Development of an mRNA Vaccine for Sars-Cov-2)
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [information-sharing.confidentiality.moderna-barda-contract-for-development-of-mrna-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2443
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-4/
            [children] => 
        )

    [information-sharing.data-management.moderna-barda-contract-for-development-of-mrna-vaccine-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 2445
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-6/
            [children] => 
        )

    [ip-ownership.access-results.moderna-barda-contract-for-development-of-mrna-vaccine] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 2440
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine/
            [children] => 
        )

    [ip-ownership.ownership-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [ip-ownership.protection-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [liability.limitation-of-liability.moderna-barda-contract-for-development-of-mrna-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2441
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-2/
            [children] => 
        )

    [other.conflict-of-interest.moderna-barda-contract-for-development-of-mrna-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 59
            [slug] => conflict-of-interest
            [title] => Conflict of Interest
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Conflict of Interest
            [provision_id] => 2444
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-5/
            [children] => 
        )

)
MPP-AbbVie License Agreement (LPV r)
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [ip-ownership.sublicensee.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 108
            [slug] => sublicensee
            [title] => Sublicenses
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Sublicenses
            [provision_id] => 1120
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpps-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1118
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-abbvie/
            [children] => 
        )

)
MPP-AbbVie Sublicense Agreement
2014
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [business-model. .mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 53
            [slug] => business-model
            [title] => Business model
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Business model
            [provision_id] => 1125
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
            [children] => 
        )

    [ip-ownership.exploitation-results.mpp-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1183
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-abbvie/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1125
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1313
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3/
            [children] => 
        )

)
MPP-BMS Sublicense & Tech Transfer Agreement
2017
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [information-sharing.technology-transfer.mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1229
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1124
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
            [children] => 
        )

    [liability.indemnity.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1314
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
            [children] => 
        )

)
MPP-BMS-Aurobindo Sublicense Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Pharmaceutical manufacturer
Drug
Commercialization
Array
(
    [ip-ownership.use-background-ip.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1122
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
            [children] => 
        )

)
MPP-Gilead License Agreement
2011
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [information-sharing.confidentiality.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1228
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-license-agreement-with-gilead-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1249
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-4/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1228
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
            [children] => 
        )

    [ip-ownership.access-results.mpp-license-agreement-with-gilead-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1143
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-2/
            [children] => 
        )

    [ip-ownership.ownership-results.mpp-license-agreement-with-gilead-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1143
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-license-agreement-with-gilead] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1114
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-gilead-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1263
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-5/
            [children] => 
        )

    [liability.limitation-of-liability.mpp-license-agreement-with-gilead-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1270
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-6/
            [children] => 
        )

)
MPP-Merck License Agreement (Raltegravir)
2015
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
  • No Issues
MPP-Pfizer License Agreement (Sutezolid)
2019
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [access-to-medicines.equitable-access.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1207
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
            [children] => 
        )

)
MPP-Univ. of Liverpool License Agreement
2015
Academic institution
Other nonprofit
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 1117
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1117
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
            [children] => 
        )

)
MPP-ViiV License Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [ip-ownership.use-background-ip.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1123
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1315
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2/
            [children] => 
        )

)
NIH Model License Agreement for Use by Non-Profit
2017
Government
Other nonprofit
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.protection-results.nih-model-license-agreement-for-use-by-non-profit-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1168
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.nih-model-license-agreement-for-use-by-non-profit] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1135
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit/
            [children] => 
        )

)
Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
2020
Biotechnology company
Funder
Vaccine manufacturer
Vaccine
Commercialization
Array
(
    [access-to-medicines.equitable-access.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 2892
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.pandemic-products.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 266
            [slug] => pandemic-products
            [title] => Pandemic Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Pandemic Products
            [provision_id] => 2890
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.pricing.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable or reasonable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Affordable or reasonable pricing
            [provision_id] => 2892
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.public-health-licenses.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 107
            [slug] => public-health-licenses
            [title] => Public health licenses
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Public health licenses
            [provision_id] => 2888
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3/
            [children] => 
        )

    [access-to-medicines.supply-purchase-of-products.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2890
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2893
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.access-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 2888
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2886
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 2886
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2/
            [children] => 
        )

    [liability.indemnity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.insurance.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.limitation-of-liability.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.warranties.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2907
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8/
            [children] => 
        )

    [open-science.open-data.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 2893
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7/
            [children] => 
        )

    [open-science.publication.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 2893
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7/
            [children] => 
        )

    [other.regulatory-strategy.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2889
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

)
Novavax–US Army Statement of Work for Rapid (WF10) Advanced Research & Development to Large Scale Manufacturing of NVX-CoV-2373 as a Vaccine for SARS-CoV-2 Coronavirus, under the Base Agreement between Novavax and Advanced Technology International
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.supply-purchase-of-products.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2739
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2740
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2736
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3/
            [children] => 
        )

    [ip-ownership.access-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 2735
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 2734
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine/
            [children] => 
        )

    [ip-ownership.ownership-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2735
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2/
            [children] => 
        )

    [ip-ownership.ownership-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2736
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3/
            [children] => 
        )

    [ip-ownership.protection-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 2738
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5/
            [children] => 
        )

    [ip-ownership.use-background-ip.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 2734
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine/
            [children] => 
        )

    [liability.limitation-of-liability.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2743
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9/
            [children] => 
        )

    [liability.warranties.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2742
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8/
            [children] => 
        )

    [open-science.publication.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 2741
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7/
            [children] => 
        )

    [other.regulatory-strategy.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2737
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 2744
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.2748] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2748
            [provision_permalink] => https://ghiaa.org/provision_document/2748/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2749
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11/
            [children] => 
        )

)
Pfizer/BioNTech-Dominican Republic Binding Term Sheet
2021
Biotechnology company
Government
Multinational pharmaceutical company
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.supply-purchase-of-products.pfizer-biontech-dominican-republic-binding-term-sheet-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 3121
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-3/
            [children] => 
        )

    [information-sharing.confidentiality.pfizer-biontech-dominican-republic-binding-term-sheet-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 3122
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-4/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.pfizer-biontech-dominican-republic-binding-term-sheet-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 3122
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.pfizer-biontech-dominican-republic-binding-term-sheet-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 3127
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-9/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.pfizer-biontech-dominican-republic-binding-term-sheet] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 3119
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet/
            [children] => 
        )

    [liability.indemnity.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 3123
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
            [children] => 
        )

    [liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3123
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
            [children] => 
        )

    [liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3124
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-6/
            [children] => 
        )

    [other.dispute-resolution.pfizer-biontech-dominican-republic-binding-term-sheet-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 267
            [slug] => dispute-resolution
            [title] => Dispute resolution
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Dispute resolution
            [provision_id] => 3125
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-7/
            [children] => 
        )

    [other.regulatory-strategy.pfizer-biontech-dominican-republic-binding-term-sheet-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 3120
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.pfizer-biontech-dominican-republic-binding-term-sheet-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3126
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-8/
            [children] => 
        )

)
Redacted Collaboration Agreement
2016
Academic institution
General Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.redacted-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1248
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-6/
            [children] => 
        )

    [information-sharing.data-management.redacted-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1232
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.redacted-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 1232
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.material-transfer.redacted-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1238
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.redacted-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1150
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement/
            [children] => 
        )

    [open-science.open-data.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1220
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
            [children] => 
        )

    [open-science.open-sciences.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1220
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
            [children] => 
        )

    [open-science.publication.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [term-and-termination.term-of-agreement.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

)
Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
2020
Government
Pharmaceutical manufacturer
Drug
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.supply-purchase-of-products.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2823
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2821
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3/
            [children] => 
        )

    [ip-ownership.access-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 2820
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 2819
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2/
            [children] => 
        )

    [ip-ownership.ownership-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2820
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
            [children] => 
        )

    [ip-ownership.ownership-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 2821
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 2819
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2/
            [children] => 
        )

    [liability.limitation-of-liability.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2824
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6/
            [children] => 
        )

    [other.regulatory-strategy.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2822
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4/
            [children] => 
        )

)
Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
2020
Government
Multinational pharmaceutical company
Pharmaceutical manufacturer
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.supply-purchase-of-products.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Supply/Purchase of Products
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Supply/Purchase of Products
            [provision_id] => 2466
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2/
            [children] => 
        )

    [business-model.royalties-and-payments.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2457
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10/
            [children] => 
        )

    [business-model.royalties-and-payments.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 2459
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9/
            [children] => 
        )

    [information-sharing.confidentiality.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 2464
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 2462
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6/
            [children] => 
        )

    [ip-ownership.access-results.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 2460
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8/
            [children] => 
        )

    [liability.limitation-of-liability.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2465
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3/
            [children] => 
        )

    [open-science.publication.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 2461
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7/
            [children] => 
        )

    [other.dispute-resolution.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development] => GHIAA2019\IssueItem Object
        (
            [ID] => 267
            [slug] => dispute-resolution
            [title] => Dispute resolution
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Dispute resolution
            [provision_id] => 2467
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development/
            [children] => 
        )

    [other.regulatory-strategy.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 54
            [parent_slug] => other
            [parent_title] => Other
            [display_title] => Other | Regulatory strategy
            [provision_id] => 2463
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5/
            [children] => 
        )

)
WHO Mutual Confidential Disclosure Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.who-mutual-confidential-disclosure-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1247
            [provision_permalink] => https://ghiaa.org/provision_document/who-mutual-confidential-disclosure-agreement/
            [children] => 
        )

)
WHO Project Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .who] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1296
            [provision_permalink] => https://ghiaa.org/provision_document/who/
            [children] => 
        )

)
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .who] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1296
            [provision_permalink] => https://ghiaa.org/provision_document/who/
            [children] => 
        )

    [ip-ownership.access-results.who-standard-framework-memorandum-of-understanding] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1156
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding/
            [children] => 
        )

    [ip-ownership.ownership-results.who-standard-framework-memorandum-of-understanding] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1156
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding/
            [children] => 
        )

    [liability.limitation-of-liability.who-standard-framework-memorandum-of-understanding-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1271
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding-2/
            [children] => 
        )

)
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .who] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1296
            [provision_permalink] => https://ghiaa.org/provision_document/who/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.who-template-material-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 1226
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.access-results.template-collaboration-agreement-with-who] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1155
            [provision_permalink] => https://ghiaa.org/provision_document/template-collaboration-agreement-with-who/
            [children] => 
        )

    [ip-ownership.ownership-results.template-collaboration-agreement-with-who] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1155
            [provision_permalink] => https://ghiaa.org/provision_document/template-collaboration-agreement-with-who/
            [children] => 
        )

    [liability.limitation-of-liability.who-template-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 2972
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-collaboration-agreement/
            [children] => 
        )

)
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.who-template-material-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1225
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-2/
            [children] => 
        )

    [information-sharing.material-transfer.who-template-material-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1225
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.who-template-material-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1108
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement/
            [children] => 
        )

    [liability.indemnity.who-template-material-transfer-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1265
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-6/
            [children] => 
        )

)